Pages

Showing posts with label Blood Cancer Research Partnership. Show all posts
Showing posts with label Blood Cancer Research Partnership. Show all posts

Tuesday, May 6, 2014

Susan Allen: Reflecting on Day 1 of the LLS Symposium in Washington DC



May 5, 2014

Hello LLS North Texas,

I set out for Washington DC on Monday May 5th, full of anticipation. On what is my 22 year anniversary of being diagnosed with Hodgkin's Lymphoma Stage 2B it is such an honor and privilege to be attending the "Leading Way to a World Without Blood Cancers.'  It is a three day event that will bring together researchers and scientist who are forging ahead to find a cure, volunteers leaders and passionate advocates all under one roof. We will focus on where we are today and where we are headed in the future to have the most impact on the LLS Mission, "A World Without Blood Cancer."

Monday afternoon we listened to a ten person Research Panel that included two transplant specialist, several research scientists, sweet Emily Whiltehead who is featured in our Fighting Fire with Fire video (who turned 11 on May 2nd), the parents of a child who lost the battle but they remain passionate about LLS, a pediatric and Adult Hematologist/Oncologist. Although all of the panelist are highly educated and shared their vast knowledge with us they also spoke from the heart about their passion to find a cure.

A theme that I heard from the panel is that they understand that treatment for blood cancer is rigorous and a challenge to the body due to the toxicity of the drugs and treatments. In researching and developing new options for patients their work is spent on being "specific targeting" of cancer cells through Genomic testing and paradigm shifting technologies.  That will help doctors focus their work down to the cell and gene where the cancer originated. Dr. Bradner stated, "It is a very special time in biomedical research and it should receive our full attention." At that time that Dr. Lou Degennaro, the acting LLS CEO and Chief Mission Officer, asked the panel, "How can LLS help, where should we focus our efforts to make the most impact?" The panelist were clear in the fact that their goal was a CURE and that means two things: 1. Cancer free/no medication,  and 2. Long term medication induced remission, citing CML and the fact that is is a chronic manageable disease using Gleevac. The main theme - when it comes to funding we CANNOT take our foot off the gas peddle, we must double down and go for it. It is Time to Complete our Mission and "Someday is today."

Our day concluded with two moving survivor stories that had everyone in the audience on their feet knowing that we are moving ahead and WE WILL get there. As far as my survivor story, wow, what a ride!  Going from 22 years ago with four little boys, the youngest 17 days old, a new diagnosis and a treatment protocol to an amazing "Survivorship Journey" and now  working for LLS. Amazing if I must say so myself.


More tomorrow on "Leading the Way to a World without Blood Cancer."

_______________________________________________________________________________


Susan Allen is the Patient Access Manager of the North Texas Chapter of The Leukemia & Lymphoma Society and author of this monthly blog series.  She is a 22-year Hodgkin's lymphoma survivor, registered nurse and a Certified Nurse Navigator.

Contact Susan:
Susan.Allen@lls.org
(972) 996-5905

Wednesday, March 26, 2014

2013 Annual Report: The Blood Cancer Research Partnership


The 2013 Annual Report for The Leukemia & Lymphoma Society (LLS) has been released.  In this series of blogs, a number of key advancements and developments will be highlighted.  This report is an in-depth look at how your fundraising dollars are being spent and the medical breakthroughs and partnerships you are so crucial in creating.

This unprecedented Blood Cancer Research Partnership will bring clinical trials to patients where they live and address one of the primary bottlenecks to new cancer therapies: the need for more patients to take part in trials.

LLS committed funding to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber companies, to develop a novel protein therapeutic that may improve outcomes for many patients with indolent lymphomas who do not respond to standard therapy with Rituxan.  Valor's biotherapeutic is produced by fusing lymphoma-seeking antibodies to tumor-cell-killing proteins in a single, genetically engineered molecule.

The APL Project:  LLS initiated a project with Anand Jillella, MD, Chief of Hematology, Oncology and Bone Marrow Transplant at Emory University, to reduce the mortality rates for patients diagnosed with acute promyelocytic leukemia (APL) by providing community oncologists/hematologists with a simple, optimized treatment protocol for the care of newly diagnosed patients with APL, a rare molecular subtype of acute myeloid leukemia.

LLS partnered with Affimed Therapeutics AG to co-fund a phase 2 trial of a novel multi-targeted anitbody in Hodgkin's lymphoma (HL) patients for whom currently available treatments have failed.  This therapeutic is directed against two different molecules, CD30 and CD16A, to bring cancer-killing immune cells directly to the HL cells.  It is a first-in-class immunotherapy designed to treat HL patients and patients with other CD30-positive malignancies.